Description
Seeking women with ovarian cancer, fallopian tube or primary peritoneal cancer that has returned or has stopped responding to previous treatment for a study testing an investigational drug for tumors expressing a protein know as folate receptor alpha (FOLR1).
Overview
Participants in this study will have their tumors tested to see if it expresses a minimum level of protein know as folate receptor alpha (FOLR1). Initially participants will be given one of two different doses of the investigational drug, then everyone will get the same dose. Treatment will be given in 21-day cycles.
What we're hoping for
We are studying the best dose of an investigational drug for ovarian cancer, fallopian tube or primary peritoneal cancer that has returned or has stopped responding to previous treatment.
Additional Information
ClinicalTrials.gov Identifier: NCT05870748